13Collaborations and Partnerships

13.1General PrinciplesFavoriteLoadingAdd to favorites

  1. 13.1.1 As active contributors to the scientific and medical community, Members partner or collaborate with Stakeholders to develop or establish programs and projects that contribute to medical/scientific advancements or to patient outcomes. Member contributions could be in the form of funding or in-kind services.
  2. 13.1.2 Members must ensure that there are no incentives to prescribe, recommend, dispense, purchase, supply approve, reimburse or administer a product in exchange for the collaborations and partnerships.
  3. 13.1.3 Support cannot be provided to an individual Stakeholder or to an entity that is controlled in fact by the individual Stakeholder or such Stakeholder’s family member, legal representative or agent.

13.2DefinitionFavoriteLoadingAdd to favorites

  1. 13.2.1 Collaborations or Partnerships are arrangements where one or more-Member companies and reputable organizations, pool skills, expertise, experience and/or resources (“contribution”) for the joint development and implementation of patient centred projects and programs and share a commitment to successful delivery. Arrangements where pharmaceutical companies simply provide funds for a program and project are not considered Collaborations and Partnerships. Each party must make a significant contribution and the outcomes must be measured.

    All programs and projects should be of mutual benefit, with the principal beneficiary being the patient.

13.3StandardsFavoriteLoadingAdd to favorites

  1. 13.3.1 Collaborations or Partnerships may be established with organizations involved in educational, health related, scientific or medical activities.
  2. 13.3.2 In contrast to grants, donations or sponsorships, in the case of Collaborations and Partnerships, it is recognized that Members will have a more active role and participation. Where such Collaborations and Partnerships involve the presence of multiple and possibly equal parties, Members are accountable for ensuring the terms governing the involvement and contribution by all parties are appropriate and would not put the Member or the Industry in disrepute.
  3. 13.3.3 Members must have a written agreement which should include but not be limited to the program and project objectives and purpose, as well the roles and responsibilities of all parties
  4. 13.3.4 Collaborations or Partnerships must be non-promotional in nature. Member companies must ensure that their collaborators and partners are appropriate and reputable and have the required capacity and skills.
  5. 13.3.5 When Collaborations or Partnerships involve an event or activity, Members must comply with requirements of Section 6.2 (Locations and Venues) and of Section 7 (Retaining the Services of a Stakeholder).
  6. 13.3.6 When Collaborations and Partnerships result in publications, those must be unbiased and accurate, and Members are held to the current scientific standards applicable to the publication in question.
  7. 13.3.7 Collaborations and Partnerships must be clearly acknowledged in accordance with Section 3.4.1.